The effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss During Immobilisatio
Completed
- Conditions
- muscle atrophy
- Registration Number
- NL-OMON29489
- Lead Sponsor
- niversity Maastricht
- Brief Summary
na
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
Male
Aged from 18-35 years
Exclusion Criteria
(Family) history of thromboembolic events
Smoking
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quadriceps cross sectional area
- Secondary Outcome Measures
Name Time Method Whole thigh muscle CSA; muscle fibre type-specific CSA and muscle fibre type-specific satellite cell content, muscle strength.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Nandrolone Decanoate's effects on muscle atrophy during immobilization?
How does Leucine supplementation compare to standard-of-care treatments for preventing muscle loss in immobilized patients?
Are there specific biomarkers that predict response to Nandrolone Decanoate and Leucine in muscle atrophy management?
What are the potential adverse events associated with Nandrolone Decanoate and Leucine combination therapy in clinical trials?
What related compounds or combination approaches are being explored for muscle atrophy treatment alongside anabolic steroids and amino acids?